Literature DB >> 36264932

Intrapulmonary shunting is a key contributor to hypoxia in COVID-19: An update on the pathophysiology.

Nikhil Mayor1, Harry Knights2,3, Aleksandra Kotwica4, Andrew Solomon Joseph Coppola5, Harriet Hunter1, Nathan Jeffreys1, Alexander Morgan2, Shivani Gupta2, James Prentice2, Rebecca Macfarlane2, Emma Russell-Jones6, Theodore Dassios6, David Russell-Jones1,7.   

Abstract

BACKGROUND: The pathophysiology of COVID-19 remains poorly understood. We aimed to estimate the contribution of intrapulmonary shunting and ventilation-to-perfusion (VA/Q) mismatch using a mathematical model to construct oxygen-haemoglobin dissociation curves (ODCs).
METHODS: ODCs were constructed using transcutaneous pulse oximetry at two different fractions of inspired oxygen (FiO2). 199 patients were included from two large district general hospitals in the South East of England from 1st to 14th January 2021. The study was supported by the National Institute of Health Research (NIHR) Clinical Research Network.
RESULTS: Overall mortality was 29%. Mean age was 68.2 years (SEM 1·2) with 46% female. Median shunt on admission was 17% (IQR 8-24.5); VA/Q was 0.61 (IQR 0.52-0.73). Shunt was 37.5% higher in deaths (median 22%, IQR 9-29) compared to survivors (16%, 8-21; p = 0.0088) and was a predictor of mortality (OR 1.04; 95% CI 1.01-1.07). Admission oxygen saturations were more strongly predictive of mortality (OR 0.91, 95% CI 0.87-0.96). There was no difference in VA/Q mismatch between deaths (0.60; IQR 0.50-0.73) and survivors (0.61; IQR 0.52-0.73; p = 0.63) and it was not predictive of mortality (OR 0.68; 95% CI 0.18-2.52; p = 0.55). Shunt negatively correlated with admission oxygen saturation (R -0.533; p<0.0001) whereas VA/Q was not (R 0.1137; p = 0.12).
INTERPRETATION: Shunt, not VA/Q mismatch, was associated with worsening hypoxia, though calculating shunt was not of prognostic value. This study adds to our understanding of the pathophysiology of hypoxaemia in COVID-19. Our inexpensive and reliable technique may provide further insights into the pathophysiology of hypoxia in other respiratory diseases.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 36264932      PMCID: PMC9584408          DOI: 10.1371/journal.pone.0273402

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.752


  17 in total

1.  Characteristics and outcomes of patients with COVID-19 at a district general hospital in Surrey, UK.

Authors:  Harry Knights; Nikhil Mayor; Kristina Millar; Matthew Cox; Evgeniya Bunova; Morgan Hughes; Jack Baker; Sanju Mathew; David Russell-Jones; Aleksandra Kotwica
Journal:  Clin Med (Lond)       Date:  2020-07-24       Impact factor: 2.659

2.  Almitrine for COVID-19 critically ill patients - a vascular therapy for a pulmonary vascular disease: Three case reports.

Authors:  Pierre Huette; Osama Abou Arab; Vincent Jounieaux; Mathieu Guilbart; Mohamed Belhout; Guillaume Haye; Hervé Dupont; Christophe Beyls; Yazine Mahjoub
Journal:  World J Clin Cases       Date:  2021-05-16       Impact factor: 1.337

Review 3.  The COVID-19 puzzle: deciphering pathophysiology and phenotypes of a new disease entity.

Authors:  Marcin F Osuchowski; Martin S Winkler; Tomasz Skirecki; Sara Cajander; Manu Shankar-Hari; Gunnar Lachmann; Guillaume Monneret; Fabienne Venet; Michael Bauer; Frank M Brunkhorst; Sebastian Weis; Alberto Garcia-Salido; Matthijs Kox; Jean-Marc Cavaillon; Florian Uhle; Markus A Weigand; Stefanie B Flohé; W Joost Wiersinga; Raquel Almansa; Amanda de la Fuente; Ignacio Martin-Loeches; Christian Meisel; Thibaud Spinetti; Joerg C Schefold; Catia Cilloniz; Antoni Torres; Evangelos J Giamarellos-Bourboulis; Ricard Ferrer; Massimo Girardis; Andrea Cossarizza; Mihai G Netea; Tom van der Poll; Jesús F Bermejo-Martín; Ignacio Rubio
Journal:  Lancet Respir Med       Date:  2021-05-06       Impact factor: 30.700

Review 4.  The pathophysiology of 'happy' hypoxemia in COVID-19.

Authors:  Sebastiaan Dhont; Eric Derom; Eva Van Braeckel; Pieter Depuydt; Bart N Lambrecht
Journal:  Respir Res       Date:  2020-07-28

5.  Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis.

Authors:  Zhaohai Zheng; Fang Peng; Buyun Xu; Jingjing Zhao; Huahua Liu; Jiahao Peng; Qingsong Li; Chongfu Jiang; Yan Zhou; Shuqing Liu; Chunji Ye; Peng Zhang; Yangbo Xing; Hangyuan Guo; Weiliang Tang
Journal:  J Infect       Date:  2020-04-23       Impact factor: 6.072

6.  Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.

Authors:  Fei Zhou; Ting Yu; Ronghui Du; Guohui Fan; Ying Liu; Zhibo Liu; Jie Xiang; Yeming Wang; Bin Song; Xiaoying Gu; Lulu Guan; Yuan Wei; Hui Li; Xudong Wu; Jiuyang Xu; Shengjin Tu; Yi Zhang; Hua Chen; Bin Cao
Journal:  Lancet       Date:  2020-03-11       Impact factor: 79.321

7.  Dexamethasone in Hospitalized Patients with Covid-19.

Authors:  Peter Horby; Wei Shen Lim; Jonathan R Emberson; Marion Mafham; Jennifer L Bell; Louise Linsell; Natalie Staplin; Christopher Brightling; Andrew Ustianowski; Einas Elmahi; Benjamin Prudon; Christopher Green; Timothy Felton; David Chadwick; Kanchan Rege; Christopher Fegan; Lucy C Chappell; Saul N Faust; Thomas Jaki; Katie Jeffery; Alan Montgomery; Kathryn Rowan; Edmund Juszczak; J Kenneth Baillie; Richard Haynes; Martin J Landray
Journal:  N Engl J Med       Date:  2020-07-17       Impact factor: 91.245

8.  SARS-CoV-2 infection causes pulmonary shunt by vasodilatation.

Authors:  Anderson Brito-Azevedo; Eduardo Costa Pinto; Gabriel Angelo de Cata Preta Corrêa; Eliete Bouskela
Journal:  J Med Virol       Date:  2020-08-02       Impact factor: 20.693

9.  Pulmonary Vascular Dilatation Detected by Automated Transcranial Doppler in COVID-19 Pneumonia.

Authors:  Alexandra S Reynolds; Alison G Lee; Joshua Renz; Katherine DeSantis; John Liang; Charles A Powell; Corey E Ventetuolo; Hooman D Poor
Journal:  Am J Respir Crit Care Med       Date:  2020-10-01       Impact factor: 21.405

10.  IL-6 and intrapulmonary shunt.

Authors:  Francisco Perez-Vizcaino; Laura Moreno; José A Lorente
Journal:  Eur Respir J       Date:  2021-07-01       Impact factor: 16.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.